Copy to clipboard 
LimaCorporate reported 2Q22 orthopedic sales of $65.5 million, +14.4% compared to 2Q21.
The company performed well in most areas of Europe and experienced a strong rebound in U.S. sales. While the APAC region remains disrupted due to COVID, Brazil was a standout performer in the ROW category. LimaCorporate expects to sustain growth through the rest of the year across its regions due to a sizeable procedure backlog.
Expanding market access is a strategic initiative for the company. So far this year, it has won FDA clearance for its PRIMA Humeral system, enlarged its APAC extremities portfolio and initiated a U.S. controlled release of the SmartSpace 3D Planner.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. Orthopedic sales and growth rates are estimated on an as-reported basis.
Orthopedic Sales by Segment
| 2Q22 | 2Q21 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $61.6 | $53.8 | $7.8 | 14.4% |
| Knees | $12.4 | $10.3 | $2.1 | 20.8% |
| Hips | $23.2 | $21.2 | $2.1 | 9.8% |
| Extremities | $25.9 | $22.3 | $3.5 | 15.9% |
| Trauma | $2.9 | $2.3 | $0.7 | 28.7% |
| Other (Promade) | $1.0 | $1.1 | ($0.2) | (14.2%) |
| Total | $65.5 | $57.2 | $8.3 | 14.4% |
| 1H22 | 1H21 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $117.4 | $101.2 | $16.2 | 16% |
| Knees | $23.7 | $19.3 | $4.4 | 23% |
| Hips | $44.6 | $39.1 | $5.5 | 14% |
| Extremities | $49.0 | $42.8 | $6.3 | 14.6% |
| Trauma | $5.3 | $4.3 | $1.0 | 24.2% |
| Other (Promade) | $2.2 | $1.6 | $0.5 | 32% |
| Total | $124.8 | $107.1 | $17.7 | 16.6% |
Orthopedic Sales by Geography
| 2Q22 | 2Q21 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $11.1 | $8.6 | $2.5 | 29.7% |
| OUS | $54.4 | $48.6 | $5.7 | 11.7% |
| EMEA | $38.6 | $34.3 | $4.3 | 12.5% |
| APAC | $9.8 | $10.9 | ($1.0) | (9.7%) |
| ROW | $5.9 | $3.4 | $2.5 | 71.7% |
| Total | $65.5 | $57.2 | $8.3 | 14.4% |
| 1H22 | 1H21 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $21.8 | $16.1 | $5.8 | 35.8% |
| OUS | $103.0 | $91.0 | $12.0 | 13.2% |
| EMEA | $75.4 | $63.3 | $12.2 | 19.3% |
| APAC | $18.7 | $20.8 | ($2.1) | (10.2%) |
| ROW | $8.9 | $6.9 | $1.9 | 28% |
| Total | $124.8 | $107.1 | $17.7 | 16.6% |
LimaCorporate reported 2Q22 orthopedic sales of $65.5 million, +14.4% compared to 2Q21.
The company performed well in most areas of Europe and experienced a strong rebound in U.S. sales. While the APAC region remains disrupted due to COVID, Brazil was a standout performer in the ROW category. LimaCorporate expects to sustain growth through...
LimaCorporate reported 2Q22 orthopedic sales of $65.5 million, +14.4% compared to 2Q21.
The company performed well in most areas of Europe and experienced a strong rebound in U.S. sales. While the APAC region remains disrupted due to COVID, Brazil was a standout performer in the ROW category. LimaCorporate expects to sustain growth through the rest of the year across its regions due to a sizeable procedure backlog.
Expanding market access is a strategic initiative for the company. So far this year, it has won FDA clearance for its PRIMA Humeral system, enlarged its APAC extremities portfolio and initiated a U.S. controlled release of the SmartSpace 3D Planner.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. Orthopedic sales and growth rates are estimated on an as-reported basis.
Orthopedic Sales by Segment
| 2Q22 | 2Q21 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $61.6 | $53.8 | $7.8 | 14.4% |
| Knees | $12.4 | $10.3 | $2.1 | 20.8% |
| Hips | $23.2 | $21.2 | $2.1 | 9.8% |
| Extremities | $25.9 | $22.3 | $3.5 | 15.9% |
| Trauma | $2.9 | $2.3 | $0.7 | 28.7% |
| Other (Promade) | $1.0 | $1.1 | ($0.2) | (14.2%) |
| Total | $65.5 | $57.2 | $8.3 | 14.4% |
| 1H22 | 1H21 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $117.4 | $101.2 | $16.2 | 16% |
| Knees | $23.7 | $19.3 | $4.4 | 23% |
| Hips | $44.6 | $39.1 | $5.5 | 14% |
| Extremities | $49.0 | $42.8 | $6.3 | 14.6% |
| Trauma | $5.3 | $4.3 | $1.0 | 24.2% |
| Other (Promade) | $2.2 | $1.6 | $0.5 | 32% |
| Total | $124.8 | $107.1 | $17.7 | 16.6% |
Orthopedic Sales by Geography
| 2Q22 | 2Q21 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $11.1 | $8.6 | $2.5 | 29.7% |
| OUS | $54.4 | $48.6 | $5.7 | 11.7% |
| EMEA | $38.6 | $34.3 | $4.3 | 12.5% |
| APAC | $9.8 | $10.9 | ($1.0) | (9.7%) |
| ROW | $5.9 | $3.4 | $2.5 | 71.7% |
| Total | $65.5 | $57.2 | $8.3 | 14.4% |
| 1H22 | 1H21 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $21.8 | $16.1 | $5.8 | 35.8% |
| OUS | $103.0 | $91.0 | $12.0 | 13.2% |
| EMEA | $75.4 | $63.3 | $12.2 | 19.3% |
| APAC | $18.7 | $20.8 | ($2.1) | (10.2%) |
| ROW | $8.9 | $6.9 | $1.9 | 28% |
| Total | $124.8 | $107.1 | $17.7 | 16.6% |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
